Tenon Medical, Inc. (TNON): Results of Operations and Financial Condition
Tenon Medical, Inc. (TNON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030193501ex99-1.htm PRESS RELEASE OF TENON MEDICAL, INC., DATED AUGUST 13, 2026 Exhibit 99.1 Tenon Medical Reports Second Quarter 2026 Financial Results ~ Second Quarter 2026 Revenue of $1.3 Million, a 127% Increase Compared to Prior Year ~ ~ Second Quarter Gross Prof
How this was made
The 30-second read
Why it matters
Traders can reassess near-term revenue trajectory (procedure volume and training ramp), gross margin durability (reusable instrument upgrades), and balance-sheet risk (cash level, convertible note maturity, and dilution from the offering).
Market read
Material company-specific disclosures: Q2 financials with strong YoY growth and margin expansion, FDA clearance, record case volume, a $4.2M offering, and a reverse split tied to Nasdaq compliance.
What to watch
Cash fell to $1.7M at June 30 from $3.8M at year-end, and convertible notes mature Sept. 11, 2026, increasing refinancing risk even after the July offering.
Background
The 8-K (Item 2.02) summarizes Tenon Medical’s Q2 2026 results and several subsequent updates, including FDA clearance, a $4.2M offering, and a 1-for-35 reverse split.
Ticker impact
Tenon Medical reported Q2 2026 revenue of $1.3M (+127% YoY), 64% gross margin, and FDA 510(k) clearance for an updated Catamaran SI Joint Fusion System.
Likely positive bias on clearance and improving gross margin, partially offset by dilution risk from the $4.2M offering and reduced cash balance.
The filing discloses multiple time-sensitive items: FDA 510(k) clearance, record case volume/training ramp, and a post-quarter $4.2M public offering, alongside a 1-for-35 reverse split and low cash ($1.7M at June 30).
Market effects
Adds a datapoint that sacro-pelvic implant procedure volumes and device cost structure can improve via instrument reclassification from disposable to reusable.
Limited, company-specific impact likely confined to US small-cap medtech sentiment.
Low; FDA clearance is US-specific and does not directly imply international regulatory outcomes.
Counterpoint
Gross margin improvement may reflect mix and fixed-cost absorption rather than durable unit economics, while the reverse split and offering highlight ongoing financing pressure.
Key entities
- companyTenon Medical, Inc.
NASDAQ-listed medical device company reporting Q2 2026 results, FDA 510(k) clearance, and a post-quarter $4.2M public offering.
- productCatamaran SI Joint Fusion System
Updated system received FDA 510(k) clearance, including instrument upgrades and reclassification from disposable to reusable.
- financingConvertible notes
$5.2M convertible notes mature Sept. 11, 2026 (extendable to Dec. 11, 2026), with partial repayment planned using July offering proceeds.